Find a Doctor or Practice Location

Are you a referring physician?
within
I am searching for a
Reset Form
Gregory L. Beatty, MD, PhD

Gregory L. Beatty, MD, PhD Physician

Assistant Professor of Medicine

Dr. Beatty is employed by Penn Medicine.

Request an Appointment
No Patient Satisfaction Reviews
Why not?

There is no publicly available rating for this medical professional for one of the following reasons:

  1. He or she is not employed by Penn Medicine.
  2. He or she does not see patients.
  3. He or she sees patients but has not yet received the minimum 30 patient satisfaction reviews in the past 12 months, ensuring that the rating is statistically reliable and a true reflection of patient satisfaction.
X

Clinical Specialties

Specialty:

  • Medical Oncology

Programs & Centers:

Board Certification:

  • Medical Oncology, 2010

Clinical Expertise:

  • Gastrointestinal Carcinoid Tumor

Description of Clinical Expertise

Dr. Beatty's clinical expertise is in the area of early clinical trials for the treatment of gastrointestinal malignancies including pancreas, esophageal and colon carcinomas. He has led the first clinical study of CD40 immunotherapy for pancreas cancer, the first in-human study of a novel inhibitor of indoleamine 2,3 deoxygenase, and is currently working to translate novel T cell adoptive therapies for pancreas cancer.

In addition to the translation of immunotherapeutic strategies for the treatment of gastrointestinal malignancies, Dr. Beatty's clinical research is focused on translating novel imaging strategies to the clinic to understand therapeutic responses to immunotherapy. His research also collaborates with radiation oncology to understand the role of radiation for activating immune responses against pancreatic carcinoma.

Based on early clinical findings supporting a role for immunotherapy in pancreatic carcinoma, Dr. Beatty's laboratory is using preclinical models of cancer to advance our understanding of the role of the immune system in regulating tumor biology with the primary goal to inform the development of novel immunotherapeutics for translation to the clinical setting.

Practice Locations and Appointments

Insurance Accepted

  • Aetna US Healthcare
  • Amerihealth Caritas
  • Amerihealth Caritas Medicare
  • Cigna
  • Cigna HealthSpring
  • Clover Health Plan
  • CVS Health
  • Devon Health Services (Americare)
  • Gateway Health Plan
  • Geisinger Health Plan
  • HealthAmerica / HealthAssurance, a Coventry Plan
  • HealthPartners
  • HealthPartners Medicare
  • HealthSmart
  • Highmark Blue Shield
  • Horizon Blue Cross Blue Shield of New Jersey
  • Humana / Choicecare
  • Independence Blue Cross (Keystone East)
  • Intergroup
  • Keystone First
  • Keystone First Medicare
  • Multiplan
  • NJ Medicaid
  • NJ Qualcare
  • Oxford Health Plan
  • PA Medicaid
  • PA Medicare
  • Preferred Health Care/LGH
  • Rail Road Medicare / Palmetto GBA
  • Remedy Partners at Penn Medicine
  • Tricare
  • United Healthcare
  • UnitedHealthcare Community Plan
  • US Family Health Plan
  • Vetrans Choice Program (6/2018 Not Active)

Education and Training

Medical School: University of Pennsylvania School of Medicine
Residency: Hospital of the University of Pennsylvania
Fellowship: Hospital of the University of Pennsylvania

Memberships

American Association For Cancer Research, National American Society Of Clinical Oncology, National

Hospital Affiliation

Dr. Beatty is employed by Penn Medicine.

Hospital Privileges:

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.

Research

Description of Research Expertise:

My laboratory incorporates both basic science research and clinical investigation to examine the role of innate immunity, in particular monocytes/macrophages, in regulating tumor biology in pancreas cancer as well as other upper gastrointestinal malignancies. Our central hypothesis is that macrophages are key regulators of tumor biology.

Clinical research in the laboratory uses patient-derived samples to understand the role of macrophage biology in metastatic disease and therapeutic efficacy.

Preclinical research in the laboratory uses a genetically engineered mouse model of pancreas cancer in combination with advanced imaging strategies to study macrophage biology within the tumor microenvironment. This preclinical research platform allows for the study of basic immune biology within the tumor microenvironment as well as the rapid screening of novel immunotherapeutic strategies, including cell and gene therapies, for the treatment of cancer.

Studies in the laboratory focus on understanding 1) the signaling pathways that regulate cross-talk between macrophages and tumor cells in vivo, 2) the role of hematopoietic and non-hematopoietic cells in regulating macrophage biology within tumors, 3) the cellular trafficking of macrophages to primary and metastatic lesions, 4) strategies to harness macrophages for anti-tumor therapy, and 5) the impact of chemotherapy/radiation therapy on macrophage biology within tumors.

Selected Publications:

Vonderheide, RH, Bajor DL, Bayne LJ, and G.L. Beatty: CD40 immunotherapy for pancreatic cancer Cancer Immunology, Immunotherapy : 2013.

Maus, M.V., Haas, A.R., Beatty, G.L., Albelda, S.M., Levine, B.L., Liu, X., Zhao, Y., Kalos, M., and C.H. June.: T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunology Research 1 : 26-31,2013 .

Bayne, L.J., Beatty, G.L., Jhala, N., Clark, C.E., Rhim, A.D., Stanger, B.Z., and R.H. Vonderheide: Tumor-derived granulocyte-macrophage colony stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer Cancer Cell 21 : 822-35.,2012 .

Rhim, A.D, Mirek, E.T., Aiello, N.M., Maitra, A., Bailey, J.M., McCallister, F., Reichert, M., Beatty, G.L., Rustgi, A.K.., Vonderheide, R.H., Leach, S.D., and B.Z. Stanger: EMT and dissemination precede pancreatic tumor formation Cell 148 : 349-61,2012.

Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun WJ, Huhn RD, Song WR, Li DG, Sharp LL, Torigian DA, O'Dwyer PJ, Vonderheide RH: CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans. Science 331 (6024): 1612-1616,2011.

Beatty GL, Smith JS, Reshef R, Patel KP, Colligon TA, Vance BA, Frey NV, Johnson FB, Porter DL, Vonderheide RH: Functional Unresponsiveness and Replicative Senescence of Myeloid Leukemia Antigen-specific CD8(+) T Cells After Allogeneic Stem Cell Transplantation. Clinical Cancer Research 15 (15): 4944-4953,2009.

Clark CE, Beatty GL, Vonderheide RH: Immunosurveillance of pancreatic adenocarcinoma: Insights from genetically engineered mouse models of cancer. Cancer Letters 279 (1): 1-7,2009.

Dominiecki ME, Beatty GL, Pan ZK, Neeson P, Paterson Y: Tumor sensitivity to IFN-gamma is required for successful antigen-specific immunotherapy of a transplantable mouse tumor model for HPV-transformed tumors. Cancer Immunology Immunotherapy 54 (5): 477-488,2005.

Beatty GL, Paterson Y: IFN-gamma signaling in antigen loss tumor variants plays a role in the bystander killing effect induced by recombinant Listeria. Federation of American Societies for Experimental Biology Journal 13 (4): A297-A297,1999.

Beatty GL, Paterson Y: IFN-gamma can promote tumor evasion of the immune system in vivo by down-regulating cellular levels of an endogenous tumor antigen. Journal Of Immunology 165 (10): 5502-5508,2000.

Beatty GL, Paterson Y: IFN-gamma-dependent inhibition of tumor angiogenesis by tumor-infiltrating CD4(+) T cells requires tumor responsiveness to IFN-gamma. Journal Of Immunology 166 (4): 2276-2282,2001.

Academic Contact Info

University of Pennsylvania Perelman School of Medicine
Smilow Center for Translational Research, 8-112
3400 Civic Center Blvd. Bldg 421

Philadelphia, PA 19104-5156
Phone: (215) 746-7764
Patient appointments: 800-789-7366 (PENN)